Anticancer Fund welcomes the proposed Biotech Act and particularly the need to simplify and streamline the Clinical Trials Regulation. Being strong supporters of resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination, we encourage the consideration of WHOs Global Action Plan for clinical trial ecosystem…
AF
Anticancer Fund
NGO · Belgium
2
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track Anticancer in PolicySpeak: request access →
Work at Anticancer Fund? so we know who speaks for it.
Their record over time
Anticancer Fund filed 2 positions on 5 Aug 2026, across 1 of the 326 legislative files tracked here.
What they argued
Anticancer Fund welcomes the proposed Biotech Act and particularly the need to simplify and streamline the Clinical Trials Regulation. Being strong supporters of resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination, we encourage the consideration of WHOs Global Action Plan for clinical trial ecosystem…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from Anticancer Fund’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.